Published January 1, 2025
| Version v1
Journal article
Open
Metformin Improves Glycemic Control and Postprandial Metabolism and Enhances Postprandial Glucagon-Like Peptide 1 Secretion in Patients With Type 2 Diabetes and Heart Failure: A Randomized, Double-Blind, Placebo-Controlled Trial
Authors/Creators
- 1. Institut klinicke a experimentalni mediciny
- 2. Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN
- 3. Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic
- 4. Institute of Endocrinology, Prague, Czech Republic
Description
This randomized trial tested the effect of metformin on glycemic control and cardiac function in patients with heart failure (HF) and type 2 diabetes while evaluating intestinal effects on selected gut microbiome products reflected by trimethylamine-N-oxide (TMAO) and gut-derived incretins. Metformin treatment improved glycemic control and postprandial metabolism and enhanced postprandial glucagon-like peptide 1 (GLP-1) secretion but did not influence cardiac function or the TMAO levels. Metabolic effects of metformin in HF may be mediated by an improvement in intestinal endocrine function and enhanced secretion of the gut-derived incretin GLP-1.
Notes
This study was supported by the project National Institute for Research of Metabolic and Cardiovascular Diseases (ProgrammeEXCELES, Project No. LX22NPO5104)—Funded by the EuropeanUnion—Next Generation EU.
Files
diaclincd240003.pdf
Additional details
Related works
- Has metadata
- 39829685 (PMID)
- Is part of
- 0891-8929 (ISSN)
- 1945-4953 (ISSN)
- References
- 10.2337/cd24-0003 (DOI)